NCT03127605 is a clinical trial of Inotuzumab Ozogamicin, sponsored by Pfizer.

Who is sponsoring NCT03127605?

NCT03127605 is sponsored by Pfizer.

What drugs are being tested in NCT03127605?

Interventions in NCT03127605: Inotuzumab Ozogamicin.

Is NCT03127605 still recruiting?

NCT03127605 is currently approved for marketing. Last updated 18 May 2020.

Last reviewed 2020-05-18 · How we verify

NCT03127605

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inotuzumab Ozogamicin - PF-05208773

APPROVED FOR MARKETING Last updated 18 May 2020

What this trial tests

trial testing Inotuzumab Ozogamicin. Approved for marketing.

Quick facts

Lead sponsor	Pfizer
Status	APPROVED FOR MARKETING
Study type	EXPANDED_ACCESS

Drugs / interventions tested

Inotuzumab Ozogamicin — full drug profile →

Sponsor

Pfizer — full company profile →

Who can join

Eligibility, any sex. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inotuzumab Ozogamicin Expanded Access Program

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Inotuzumab Ozogamicin

Trials testing the same drug.

NCT06287229 — Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients · Phase 1, PHASE2 · recruiting
NCT06087419 — A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Ve · Phase 1, PHASE2 · unknown
NCT05597085 — A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again · completed
NCT05940961 — Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL · Phase 2 · recruiting
NCT07238907 — A Multi-center Retrospective Study of INO Treating B-ALL · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03127605 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 18 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03127605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing